Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 24, 2026.

Human T Cell Response to Dengue Virus Infection

Yuan Tian, Alba Grifoni, Alessandro Sette and 1 more

Frontiers in Immunology · 2019 · Review · CC BY

doi:10.3389/fimmu.2019.02125

Abstract

DENV is a major public health problem worldwide, thus underlining the overall significance of the proposed Program. The four dengue virus (DENV) serotypes (1-4) cause the most common mosquito-borne viral disease of humans, with 3 billion people at risk for infection and up to 100 million cases each year, most often affecting children. The protective role of T cells during viral infection is well-established. Generally, CD8 T cells can control viral infection through several mechanisms, including direct cytotoxicity, and production of pro-inflammatory cytokines such as IFN-γ and TNF-α. Similarly, CD4 T cells are thought to control viral infection through multiple mechanisms, including enhancement of B and CD8 T cell responses, production of inflammatory and anti-viral cytokines, cytotoxicity, and promotion of memory responses. To probe the phenotype of virus-specific T cells, epitopes derived from viral sequences need to be known. Here we discuss the identification of CD4 and CD8 T cell epitopes derived from DENV and how these epitopes have been used by researchers to interrogate the phenotype and function of DENV-specific T cell populations.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 24, 2026. Paragraph numbers are ours, so an answer can point at one.

DENV Infection and the Complex Roles of T Cells

Dengue virus (DENV) belongs to the genus Flavivirus and is closely related to several other flaviviruses including Zika virus (ZIKV), yellow fever virus (YFV), Japanese encephalitis virus (JEV), and West Nile virus (WNV). DENV is a serious public health issue especially in tropical and subtropical areas, and it is estimated that ~390 million people are infected yearly with DENV. DENV infection is associated with a range of clinical manifestations, from asymptomatic to more severe presentations including dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). There is currently no specific therapy available for the treatment of dengue diseases other than supportive care. Furthermore, Dengvaxia® (Sanofi Pasteur), the first licensed DENV vaccine, is associated with efficacy and safety concerns. Sridhar et al. integratively analyzed data from three clinical trials and reported that Dengvaxia® increases the risk of severe dengue and hospitalization among vaccinees who have not been exposed to DENV before the vaccination. In order to develop effective DENV therapeutics and vaccines, it is important to define immunological correlates of protection against DENV infection as well as biomarkers that can be used to access their safety and efficacy.

Although T cells have important functions in combating viral pathogens, both pathological and protective effects of T cells have been reported in the context of DENV infection. According to T cell original antigenic sin, cross-reactive T cells that are specific for a primary DENV serotype become predominant during a secondary heterologous infection. Consequently, the expansion of preexisting cross-reactive and low-affinity memory T cells results in ineffective viral control and contributes to immunopathology and severe dengue disease through excessive production of inflammatory cytokines. In contrast to the implications of original antigenic sin, several lines of evidence indicate that T cells contribute to the control of DENV infection. Murine studies demonstrate that CD4 T cells and especially CD8 T cells can play a protective role against DENV challenge. Furthermore, HLA alleles associated with protection from severe dengue disease are also associated with strong and multifunctional T cell responses, supporting the notion that T cells have protective functions during DENV infection. The main characteristic of an efficient vaccine is the prophylactic effect provided by protective neutralizing antibodies. Therefore, it is possible that in Dengvaxia® vaccines, native conserved masked conformational DENV (1–4) epitopes are not unmasked and therefore not accessible for highly neutralizing and broadly protective antibodies. Nevertheless, Dengvaxia® is a yellow fever dengue chimeric vaccine and lacks DENV non-structural (NS) proteins that contain a large proportion of T cell epitopes. Therefore, the suboptimal efficacy of Dengvaxia® may partially due to its defective ability to induce T cell responses. Indeed, a single dose of the live attenuated tetravalent DENV vaccine TV003 provides complete protection against infection with a DENV-2 challenge virus, potentially highlighting the importance of harnessing the protective functions of both humoral and cellular antiviral immunity.

Metadata Analysis of DENV-Derived CD4 and CD8 T Cell Epitopes

Human antigen-specific T cell immune responses are driven by two factors that are host specific. First the capability of antigen-derived peptides to be bound and presented in the context of HLA class I and II molecules. Second, the immunogenicity of those peptides that depends on the capability of T cells to recognize through T cell receptor (TCR) the HLA-peptide complex and trigger T-cell specific immune responses. Several studies have identified the DENV epitopes able to induce CD8 and/or CD4 T cells specific-response and consecutively the immunodominance of DENV proteins for DENV-specific T cell response. In this review, we summarize previous published data of all the DENV-epitopes experimentally identified by us and others by performing an overall analysis of data available in Immune Epitope Database (www.IEDB.org).

The IEDB database was queried on July 8th 2019 using the following search parameters: Positive assays only, Organism: Dengue virus (ID:12637), No B cell assays, No MHC ligand assays, Host: Homo sapiens (Human). This query retrieved a total of 57 different publications (Table 1). Most of the studies were focused on NS3 protein or multiple DENV proteins defined as immunodominant region based on previous studies (Table 1). Additional studies evaluated the full DENV polyprotein targeting either HLA-Transgenic DENV infected mice or human samples. Specifically, we considered human samples derived from different geographical locations and collected from either healthy DENV seropositive blood donors DENV or patients during acute dengue infection or healthy donor after experimental vaccination with dengue virus (Table 1). A total of 2191 epitopes were described in the 57 references retrieved by the query (Table 1); of those, 825 were restricted by HLA class I molecules, and 1345 epitopes were restricted by HLA class II. To define the most dominant epitopes, we considered epitopes that were reported positive in multiple donors and/or multiple studies. For example, the NS31608−1618 is the most dominant HLA class I epitope, being independently identified by several studies also incorporating different amino acid variants (Supplementary Table 1A). Conversely, in the case of HLA class II molecules the C50−64 and C72−86 epitopes are examples of dominant epitopes, recognized in the majority of donors tested (12 positive out of 17 and 9 positive out of 11, respectively) in several independent studies. Supplementary Tables 1A,B list the most dominant class I and class II epitopes. Specifically, to identify the top ~80 epitopes we selected class I epitopes recognized in 5 donors or more (84 epitopes), and class II epitopes recognized in 8 donors of more (77 epitopes).

Immunodominant DENV Proteins Recognized by CD4 and CD8 T Cell

Dissecting the immunodominance of T cell response has considerable implications in vaccine design as the first licensed Dengvaxia® vaccine (Sanofi Pasteur) is composed of DENV structural proteins (prM, E) in a yellow fever backbone while both TV003 (NIH) and TDV (Takeda) vaccines contains both DENV structural and non-structural proteins. To assess DENV immunodominance without the bias of adding multiple studies that take in consideration only a single or few DENV proteins, we focused on the 14 studies performed on the full DENV polyprotein and summarized in Table 1.

Epitopes derived from those 14 studies have been extracted from IEDB, redundant epitopes independently defined in donors with different HLA restriction have been included to give prominence to promiscuous peptides able to be presented and recognized by different HLA molecules. Finally, epitopes have been divided based on class I or class II restriction and plotted on a DENV reference sequence (ID:12637) by using the Immunobrowser tool (http://tools.iedb.org/immunomebrowser/) freely available on the IEDB. Figure 1 shows the immunodominance of CD8 (Figure 1A, HLA class I restriction) and CD4 T cells (Figure 1B, HLA class II restriction), respectively.

CD8 T cell responses targets mainly NS3 protein, followed by Capsid, NS5 and NS4A/B proteins (Figure 1A). NS3 immunodominance is confirmed throughout all the different studies used for the analysis, representing the most frequent target of CD8 T cell response, disregarding geographical location, and HLA restriction.

Conversely, CD4 T cell responses targets mainly Capisd followed by Envelope, NS3, NS2A/B, and NS5 proteins (Figure 1B). Capsid immunodominance is consistently identified in all the different studies analyzed, representing the most frequent target of CD4 T cell response. Finally, protein immunodominance for both CD4 and CD8 T cells is also function of the multiple exposure of DENV infection, that tends to skew protein immunodominance toward epitopes highly conserved across the different DENV serotypes as previously reported. Overall, T cell protein immunodominance is quite complex and widely focused on different protein targets, suggesting that in order to trigger an efficient DENV-specific T cell response both Structural (C, prM, Envelope) and Non-Structural (NS1-5) proteins are required.

Megapool Approach to Detect DENV-Specific T Cell Responses

Epitope identification studies have provided the basis for phenotyping DENV-specific T cell responses directly ex vivo without the need for in vitro stimulation that could potentially alter T cell phenotypes. Utilizing the knowledge of the epitopes recognized we developed the megapool approach, which allows for combining a large number of peptides into one peptide pool based on sequential lyophilization. This enables detection of DENV-specific T cell responses irrespective of HLA types and DENV serotypes in various immunological contexts where only small amounts of blood are available. DENV megapools have been generated for both CD4 and CD8 T cells, which consist of 180 and 268 peptides, respectively. These peptides are pooled, lyophilized, and resuspended to form a master mix, which is then used to stimulate T cell ex vivo. DENV CD4 and CD8 megapools account for 62 and 90% of the IFN-γ response in Sri Lankan and Nicaraguan cohorts, respectively, and have been validated in different geographical locations supporting their global applicability.

DENV-Specific CD8 T Cells: Activated, Skin-Homing, and Functional

Using tetramers incorporating three variants of the HLA-A*1101-restricted DENV NS3133−142 epitope, Friberg et al. reported that cross-reactive CD8 T cells develop following both primary and secondary DENV infections and that the magnitude of tetramer+ CD8 T cell response does not correlated with disease severity. Although tetramer+ CD8 T cells upregulate the activation marker CD38 during the acute phase of infection, the phenotype of these DENV-specific CD8 T cells was not further assessed in this study. More recent studies using DENV peptide pools shows that higher magnitude and more polyfunctional CD8 T cell responses correlate with HLA alleles that are associated with reduced risk of severe dengue disease, which is consistent with the report that the frequency of DENV-specific cytokine-producing CD8 T cells is higher among children who subsequently developed subclinical secondary infection than those who developed symptomatic secondary infection. Using a pool containing 268 CD8 T cell epitopes derived from DENV (termed megapool), de Alwis et al. demonstrated that the majority of DENV-specific IFN-γ+ CD8 T cells have a CD45RA−CCR7− effector memory (Tem) or CD45RA+CCR7− effector memory re-expressing CD45RA (Temra) phenotype. Notably, DENV-specific CD8 T cells are also associated with increased PD-1 expression in donors expressing the immunodominant allele HLA-B*35:01. In contrast to classical exhausted CD8 T cells, these DENV-specific PD-1+ CD8 T cells do not co-express other exhaustion makers and are apparently proliferative and functional, suggesting that PD-1 may serve as a marker of activated and highly functional antigen-specific CD8 T cells in the context of DENV infection.

Since DENV infection initiates at the site of the mosquito bite in the host skin, it is possible that CD8 T cells may migrate to the site of infection and mediate localized responses. Indeed, DENV NS3 27-specific CD8 T cells in the periphery blood upregulate the expression of several chemokine receptors including CCR5, CXCR3, and CXCR6 as well as the skin-homing molecule cutaneous lymphocyte-associated antigen (CLA) during acute DENV infection. Moreover, DENV-specific CD8 T cells are readily detectable in the skin of DENV-infected individuals at the acute stage, suggesting that these cells may exert effector functions at the site of infection. Tissue-resident memory T (Trm) cells reside in non-lymphoid tissues including the skin and can serve as a front line of defense against invading pathogens such as vaccinia virus. It would be interesting to investigate whether DENV-specific CD8 T cells could differentiate into Trm cells in the skin that may mount rapid and localized protective immunity upon reinfection.

Comprehensive transcriptomic profiling of DENV-specific CD8 T cells has also been carried out. Chandele et al. performed microarray analysis on HLA-DR+CD38+ activated CD8 T cells isolated from the PBMCs of DENV-infected patients and found that these cells upregulate genes involved in T cell proliferation, activation, migration and cytotoxicity. Interestingly, HLA-DR+CD38+ CD8 T cells also display increased expression of multiple inhibitory receptors and downregulate several genes that are involved in TCR signaling. A more recent study from our group characterized the transcriptomic profiles of DENV-specific CD8 Tem and Temra subsets identified by their production of IFN-γ following simulation with the megapool of DENV-derived epitopes. DENV-specific Tem and especially Temra cells display specialized gene expression profiles and upregulated genes that are associated with activation, co-stimulation, and effector functions, which is consistent with the previous study from Chandele et al. Since these DENV-specific Tem and Temra cells were isolated from healthy donors with secondary DENV infection, these studies suggest that DENV-specific CD8 T cell populations may maintain an activated phenotype in donors that have been infected multiple times with DENV. Interestingly, DENV-specific Temra cells may have higher expression of a few killer cell immunoglobulin-like receptor (KIR) genes including KIR2DL3 by comparison with DENV-specific Tem cells. In addition, DENV-specific CD8 T cells may show preferential usage of TCR beta-chain variable (TRBV) genes, which is in line with the report that DENV NS3133-specific CD8 T cells targeting HLA-A*11:01-restricted epitope variants derived from DENV1, DENV3, and DENV4 but not DENV2 preferentially use a few TRBV segments including TRBV9, TRBV12-3/4, and especially TRBV11-2.

DENV-Specific CD4 T Cells: A Tale of Cytotoxicity

The majority of antigen-specific CD4 T cells differentiate into T helper type 1 (Th1) and follicular helper T (Tfh) cells following viral infections and provide help to CD8 T cells and B cells. Indeed, DENV-specific CD4 T cells produce Th1 cell-associated cytokines including IFN-γ, TNF-α, and IL-2 following both infection and vaccination. In addition, DENV-specific CD4 T cells with cytotoxic activity have been reported by numerous studies and their frequency may be lower in patients with more severe dengue disease. Interestingly, a subset human CD4 T cells, which is CD45RA+CCR7− and termed effector memory re-expressing CD45RA T (Temra) cells, expands in individuals that have been infected with DENV multiple times, and the frequency of DENV-specific CD4 Temra cells is higher in donors expressing an HLA allele associated with protection from severe dengue disease. Despite the production of IFN-γ, these cells may not represent classical Th1 cells as they lack the expression of CXCR3. CD4 Temra cells have increased expression of several cytotoxic molecules including CD107a, perforin, granzyme B as well as the CX3CL1 (fractalkine) receptor, CX3CR1. Notably, CX3CR1 has recently been reported to be a member of a 20-gene set that can predict severe dengue disease. Subsequent transcriptomic profiling studies further revealed the gene expression patterns and heterogeneity of CD4 Temra cells and identified additional phenotypic markers such as GPR56 and CD244 that are specifically expressed by cytotoxic CD4 Temra cells and confirmed their expression on DENV-specific Temra cells. Additionally, cytotoxic CD4 Temra cells may have undergone extensive clonal expansions based upon TCR analysis, supporting the notion that these cells are induced by repeated DENV infections.

Both Foxp3+ regulatory T (Treg) cells and Foxp3− type 1 regulatory T (Tr1) cells can suppress inflammation and exert immunoregulatory effects. However, their functional significance in the context of DENV infection is less well-defined. It has been reported that the frequency of Treg cells and the ratio of Treg cells to effector T cells are significantly higher during acute DENV infection than after recovery in patients with mild disease but not in those with severe disease. However, subsequent studies indicate that the frequency of Treg cells is not associated with viral load or disease severity. Therefore, whether and how Treg and Tr1 cells influence antiviral immune response and disease progression during DENV infection warrants further investigation.

T cells help to B cells is provided by a CD4 T cells subset termed follicular T helper cells (Tfh). Tfh cells have been associated with protective roles in human infectious disease and vaccinees. They provide several forms of T cell help to B cells such as signals that promote survival, proliferation, plasma cell differentiation, hypermutation, class-switch recombination, adhesion and chemoattraction (cell migration). Tfh cells are essential for the generation of most isotype switched and affinity matured antibodies, and therefore they have an obvious role in protective immunity against pathogens. A recent breakthrough has been the ability to detect Tfh cells in peripheral blood thus allowing their assessment in PBMC samples based on surface markers. A central marker of Tfh cells is the CXC-chemokine receptor 5 (CXCR5) which is required for T and B cells to enter into follicles. OX40, and PD-L1 have further been identified as TCR activation-dependent markers of human Tfh cells. Recent studies have reported an expansion of peripheral Tfh cells in DENV-infected children during the acute phase. Furthermore, Tfh cells are more abundant in patients with secondary DENV infection and in those who developed a more severe dengue disease. Although Tfh cells has been shown to promote DENV-specific antibody responses in mice, the differentiation and functional significance of DENV-specific Tfh cells in humans warrants further investigation.

Conclusion and Perspective

All DENV-specific T cell phenotypes discussed in this review as well as the markers they express are summarized in Figure 2 and Table 2, respectively. Comprehensive epitope identification over the last few years has provided the tools that allow one to probe for DENV specific T cell responses in donors exposed to natural infection and vaccination. Global assessment of dengue virus-specific CD4 and CD8 T cell responses in dengue-endemic areas led to the development of new tools (megapools) that allow analysis of small samples typically available from pediatric and hospital cohorts. It has also been demonstrated that DENV-specific CD4 and CD8 responses are more complex than previously thought, with different subsets revealed by in depth phenotypic and transcriptomic analyses. The hypothesis that these different subsets have unique roles and dictate and shape clinical outcomes and vaccine efficacy will have to be explored in the near future.

Author Contributions

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 116

  1. 1.

    Burke D Monath T Flaviviruses. In: Knipe D Howley P, editors. Field's Virology. Philadelphia: Lippincott, Williams and Wilkins (2001 ). p. 1043–126.

    Not in our library

  2. 2.

    Bhatt S Gething PW Brady OJ Messina JP Farlow AW Moyes CL. The global distribution and burden of dengue. Nature. (2013 ) 496:50a4–7.

    Not in our library10.1038/nature12060

  3. 3.

    Sabchareon A Wallace D Sirivichayakul C Limkittikul K Chanthavanich P Suvannadabba S. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet. (2012 ) 380:1559–67.

    Not in our library10.1016/s0140-6736(12)61428-7

  4. 4.

    Villar L Dayan GH Arredondo-Garcia JL Rivera DM Cunha R Deseda C. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. (2015 ) 372:113–23.

    Not in our library10.1056/nejmoa1411037

  5. 5.

    Hadinegoro SR Arredondo-Garcia JL Capeding MR Deseda C Chotpitayasunondh T Dietze R. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. (2015 ) 373:1195–206.

    Not in our library10.1056/nejmoa1506223

  6. 6.

    Capeding MR Tran NH Hadinegoro SR Ismail HI Chotpitayasunondh T Chua MN. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. (2014 ) 384:1358–65.

    Not in our library10.1016/s0140-6736(14)61060-6

  7. 7.

    Halstead SB. Dengvaxia sensitizes seronegatives to vaccine enhanced disease regardless of age. Vaccine. (2017 ) 35:6355–8.

    Not in our library10.1016/j.vaccine.2017.09.089

  8. 8.

    Sridhar S Luedtke A Langevin E Zhu M Bonaparte M Machabert T. Effect of dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med. (2018 ) 379:327–40.

    Not in our library10.1056/nejmoa1800820

  9. 9.

    Rothman AL. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol. (2011 ) 11:532–43.

    Not in our library10.1038/nri3014

  10. 10.
    T-Cell Immunity to Infection with Dengue Virus in Humans · 2014
    No notice
  11. 11.

    Screaton G Mongkolsapaya J Yacoub S Roberts C. New insights into the immunopathology and control of dengue virus infection. Nat Rev Immunol. (2015 ) 15:745–59.

    Not in our library10.1038/nri3916

  12. 12.

    Tian Y Sette A Weiskopf D. Cytotoxic CD4 T cells: differentiation, function, and application to dengue virus infection. Front. Immunol. (2016 ) 7:531.

    Not in our library10.3389/fimmu.2016.00531

  13. 13.

    Ngono AE Shresta S. Immune response to dengue and Zika. Annu Rev Immunol. (2018 ) 36:279–308.

    Not in our library10.1146/annurev-immunol-042617-053142

  14. 14.

    St. John AL Rathore APS. Adaptive immune responses to primary and secondary dengue virus infections. Nat Rev Immunol. (2019 ) 19:218–30.

    Not in our library10.1038/s41577-019-0123-x

  15. 15.

    Halstead SB Rojanasuphot S Sangkawibha N. Original antigenic sin in dengue. Am J Trop Med Hyg. (1983 ) 32:154–6.

    Not in our library10.4269/ajtmh.1983.32.154

  16. 16.

    Mongkolsapaya J Dejnirattisai W Xu XN Vasanawathana S Tangthawornchaikul N Chairunsri A. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med. (2003 ) 9:921–7.

    Not in our library10.1038/nm887

  17. 17.

    Prestwood TR Morar MM Zellweger RM Miller R May MM Yauch LE. Gamma interferon. (IFN-gamma) receptor restricts systemic dengue virus replication and prevents paralysis in IFN-alpha/beta receptor-deficient mice. J Virol. (2012 ) 86:12561–70.

    Not in our library10.1128/jvi.06743-11

  18. 18.

    Zompi S Santich BH Beatty PR Harris E. Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells. J Immunol. (2012 ) 188:404–16.

    Not in our library10.4049/jimmunol.1102124

  19. 19.

    Yauch LE Zellweger RM Kotturi MF Qutubuddin A Sidney J Peters B. A protective role for dengue virus-specific CD8+ T cells. J Immunol. (2009 ) 182:4865–73.

    Not in our library10.4049/jimmunol.0801974

  20. 20.

    Yauch LE Prestwood TR May MM Morar MM Zellweger RM Peters B. CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination. J Immunol. (2010 ) 185:5405–16.

    Not in our library10.4049/jimmunol.1001709

  21. 21.

    Zellweger RM Tang WW Eddy WE King K Sanchez MC Shresta S. CD8+ T cells can mediate short-term protection against heterotypic dengue virus reinfection in mice. J Virol. (2015 ) 89:6494–505.

    Not in our library10.1128/jvi.00036-15

  22. 22.
    Protective Role of Cross-Reactive CD8 T Cells Against Dengue Virus Infection · 2016
    Not checked
  23. 23.

    Zellweger RM Miller R Eddy WE White LJ Johnston RE Shresta S. Role of humoral versus cellular responses induced by a protective dengue vaccine candidate. PLoS Pathog. (2013 ) 9:e1003723.

    Not in our library10.1371/journal.ppat.1003723

  24. 24.

    Zellweger RM Eddy WE Tang WW Miller R Shresta S. CD8+ T cells prevent antigen-induced antibody-dependent enhancement of dengue disease in mice. J Immunol. (2014 ) 193:4117–24.

    Not in our library10.4049/jimmunol.1401597

  25. 25.

    Grifoni A Angelo MA Lopez B O'Rourke PH Sidney J Cerpas C. Global assessment of dengue virus-specific CD4. (+) T cell responses in dengue-endemic areas. Front Immunol. (2017 ) 8:1309.

    Not in our library10.3389/fimmu.2017.01309

  26. 26.

    Weiskopf D Bangs DJ Sidney J Kolla RV De Silva AD de Silva AM. Dengue virus infection elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated with protective immunity. Proc Natl Acad Sci USA. (2015 ) 112:E4256–63.

    Not in our library10.1073/pnas.1505956112

  27. 27.

    de Alwis R Bangs DJ Angelo MA Cerpas C Fernando A Sidney J. Immunodominant dengue virus-specific CD8+ T cell responses are associated with a memory PD-1+ phenotype. J Virol. (2016 ) 90:4771–9.

    Not in our library10.1128/jvi.02892-15

  28. 28.

    Weiskopf D Angelo MA de Azeredo EL Sidney J Greenbaum JA Fernando AN. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci USA. (2013 ) 110:E2046–53.

    Not in our library10.1073/pnas.1305227110

  29. 29.

    Rivino L Kumaran EA Jovanovic V Nadua K Teo EW Pang SW. Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection. J Virol. (2013 ) 87:2693–706.

    Not in our library10.1128/jvi.02675-12

  30. 30.

    Halstead SB. Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? There is only one true winner. Cold Spring Harb Perspect Biol. (2018 ) 10:a030700.

    Not in our library10.1101/cshperspect.a030700

  31. 31.

    Kirkpatrick BD Whitehead SS Pierce KK Tibery CM Grier PL Hynes NA. The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model. Sci Transl Med. (2016 ) 8:330ra36.

    Not in our library10.1126/scitranslmed.aaf1517

  32. 32.

    Jaiswal S Pazoles P Woda M Shultz LD Greiner DL Brehm MA. Enhanced humoral and HLA-A2-restricted dengue virus-specific T-cell responses in humanized BLT NSG mice. Immunology. (2012 ) 136:334–43.

    Not in our library10.1111/j.1365-2567.2012.03585.x

  33. 33.

    Culshaw A Ladell K Gras S McLaren JE Miners KL Farenc C. Germline bias dictates cross-serotype reactivity in a common dengue-virus-specific CD8. (+) T cell response. Nat Immunol. (2017 ) 18:1228–37.

    Not in our library10.1038/ni.3850

  34. 34.

    Friberg H Burns L Woda M Kalayanarooj S Endy TP Stephens HA. Memory CD8+ T cells from naturally acquired primary dengue virus infection are highly cross-reactive. Immunol Cell Biol. (2011 ) 89:122–9.

    Not in our library10.1038/icb.2010.61

  35. 35.

    Friberg H Bashyam H Toyosaki-Maeda T Potts JA Greenough T Kalayanarooj S. Cross-reactivity and expansion of dengue-specific T cells during acute primary and secondary infections in humans. Sci Rep. (2011 ) 1:51.

    Not in our library10.1038/srep00051

  36. 36.

    Zivny J Kurane I Leporati AM Ibe M Takiguchi M Zeng LL. A single nine-amino acid peptide induces virus-specific, CD8+ human cytotoxic T lymphocyte clones of heterogeneous serotype specificities. J Exp Med. (1995 ) 182:853–63.

    Not in our library10.1084/jem.182.3.853

  37. 37.

    Livingston PG Kurane I Dai LC Okamoto Y Lai CJ Men R. Dengue virus-specific, HLA-B35-restricted, human CD8+ cytotoxic T lymphocyte. (CTL) clones. Recognition of NS3 amino acids 500 to 508 by CTL clones of two different serotype specificities. J Immunol. (1995 ) 154:1287–95.

    Not in our library

  38. 38.

    Zivny J DeFronzo M Jarry W Jameson J Cruz J Ennis FA. Partial agonist effect influences the CTL response to a heterologous dengue virus serotype. J Immunol. (1999 ) 163:2754–60.

    Not in our library

  39. 39.

    Zivna I Green S Vaughn DW Kalayanarooj S Stephens HA Chandanayingyong D. T cell responses to an HLA-B*07-restricted epitope on the dengue NS3 protein correlate with disease severity. J Immunol. (2002 ) 168:5959–65.

    Not in our library10.4049/jimmunol.168.11.5959

  40. 40.

    Sanchez V Gimenez S Tomlinson B Chan PK Thomas GN Forrat R. Innate and adaptive cellular immunity in flavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells. (VDV3). Vaccine. (2006 ) 24:4914–26.

    Not in our library10.1016/j.vaccine.2006.03.066

  41. 41.

    Mongkolsapaya J Duangchinda T Dejnirattisai W Vasanawathana S Avirutnan P Jairungsri A. T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal? J Immunol. (2006 ) 176:3821–9.

    Not in our library10.4049/jimmunol.176.6.3821

  42. 42.

    Chang CX Tan AT Or MY Toh KY Lim PY Chia AS. Conditional ligands for Asian HLA variants facilitate the definition of CD8+ T-cell responses in acute and chronic viral diseases. Eur J Immunol. (2013 ) 43:1109–20.

    Not in our library10.1002/eji.201243088

  43. 43.

    Piazza P Campbell D Marques E Hildebrand WH Buchli R Mailliard R. Dengue virus-infected human dendritic cells reveal hierarchies of naturally expressed novel NS3 CD8 T cell epitopes. Clin Exp Immunol. (2014 ) 177:696–702.

    Not in our library10.1111/cei.12373

  44. 44.

    Kurane I Dai LC Livingston PG Reed E Ennis FA. Definition of an HLA-DPw2-restricted epitope on NS3, recognized by a dengue virus serotype-cross-reactive human CD4+ CD8- cytotoxic T-cell clone. J Virol. (1993 ) 67:6285–8.

    Not in our library10.1128/jvi.67.10.6285-6288.1993

  45. 45.

    Zeng L Kurane I Okamoto Y Ennis FA Brinton MA. Identification of amino acids involved in recognition by dengue virus NS3-specific, HLA-DR15-restricted cytotoxic CD4+ T-cell clones. J Virol. (1996 ) 70:3108–17.

    Not in our library10.1128/jvi.70.5.3108-3117.1996

  46. 46.

    Okamoto Y Kurane I Leporati AM Ennis FA. Definition of the region on NS3 which contains multiple epitopes recognized by dengue virus serotype-cross-reactive and flavivirus-cross-reactive, HLA-DPw2-restricted CD4+ T cell clones. J General Virol. (1998 ) 79(Pt 4):697–704.

    Not in our library10.1099/0022-1317-79-4-697

  47. 47.

    Kurane I Zeng L Brinton MA Ennis FA. Definition of an epitope on NS3 recognized by human CD4+ cytotoxic T lymphocyte clones cross-reactive for dengue virus types 2, 3, and 4. Virology. (1998 ) 240:169–74.

    Not in our library10.1006/viro.1997.8925

  48. 48.

    Mangada MM Rothman AL. Altered cytokine responses of dengue-specific CD4+ T cells to heterologous serotypes. J Immunol. (2005 ) 175:2676–83.

    Not in our library10.4049/jimmunol.175.4.2676

  49. 49.

    Moran E Simmons C Chau NV Luhn K Wills B Phuong Dung N. Preservation of a critical epitope core region is associated with the high degree of flaviviral cross-reactivity exhibited by a dengue-specific CD4+ T cell clone. Eur J Immunol. (2008 ) 38:1050–7.

    Not in our library10.1002/eji.200737699

  50. 50.

    Kurane I Okamoto Y Dai LC Zeng LL Brinton MA Ennis FA. Flavivirus-cross-reactive, HLA-DR15-restricted epitope on NS3 recognized by human CD4+ CD8- cytotoxic T lymphocyte clones. J General Virol. (1995 ) 76(Pt 9):2243–9.

    Not in our library10.1099/0022-1317-76-9-2243

  51. 51.

    Guy B Nougarede N Begue S Sanchez V Souag N Carre M. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine. (2008 ) 26:5712–21.

    Not in our library10.1016/j.vaccine.2008.08.019

  52. 52.

    Lim MQ Kumaran EAP Tan HC Lye DC Leo YS Ooi EE. Cross-reactivity and anti-viral function of dengue capsid and NS3-specific memory T cells toward zika virus. Front Immunol. (2018 ) 9:2225.

    Not in our library10.3389/fimmu.2018.02225

  53. 53.

    Townsley E Woda M Thomas SJ Kalayanarooj S Gibbons RV Nisalak A. Distinct activation phenotype of a highly conserved novel HLA-B57-restricted epitope during dengue virus infection. Immunology. (2014 ) 141:27–38.

    Not in our library10.1111/imm.12161

  54. 54.

    Wen J Duan Z Jiang L. Identification of a dengue virus-specific HLA-A*0201-restricted CD8+ T cell epitope. J Med Virol. (2010 ) 82:642–8.

    Not in our library10.1002/jmv.21736

  55. 55.

    Testa JS Shetty V Sinnathamby G Nickens Z Hafner J Kamal S. Conserved MHC class I-presented dengue virus epitopes identified by immunoproteomics analysis are targets for cross-serotype reactive T-cell response. J Infect Dis. (2012 ) 205:647–55.

    Not in our library10.1093/infdis/jir814

  56. 56.

    Simmons CP Dong T Chau NV Dung NT Chau TN Thao le TT. Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections. J Virol. (2005 ) 79:5665–75.

    Not in our library10.1128/jvi.79.9.5665-5675.2005

  57. 57.

    Duan Z Guo J Huang X Liu H Chen X Jiang M. Identification of cytotoxic T lymphocyte epitopes in dengue virus serotype 1. J Med Virol. (2015 ) 87:1077–89.

    Not in our library10.1002/jmv.24167

  58. 58.

    Imrie A Meeks J Gurary A Sukhbataar M Kitsutani P Effler P. Differential functional avidity of dengue virus-specific T-cell clones for variant peptides representing heterologous and previously encountered serotypes. J Virol. (2007 ) 81:10081–91.

    Not in our library10.1128/jvi.00330-07

  59. 59.

    Bashyam HS Green S Rothman AL. Dengue virus-reactive CD8+ T cells display quantitative and qualitative differences in their response to variant epitopes of heterologous viral serotypes. J Immunol. (2006 ) 176:2817–24.

    Not in our library10.4049/jimmunol.176.5.2817

  60. 60.

    Nascimento EJ Mailliard RB Khan AM Sidney J Sette A Guzman N. Identification of conserved and HLA promiscuous DENV3 T-cell epitopes. PLoS Negl Trop Dis. (2013 ) 7:e2497.

    Not in our library10.1371/journal.pntd.0002497

  61. 61.

    Townsley E O'Connor G Cosgrove C Woda M Co M Thomas SJ. Interaction of a dengue virus NS1-derived peptide with the inhibitory receptor KIR3DL1 on natural killer cells. Clin Exp Immunol. (2016 ) 183:419–30.

    Not in our library10.1111/cei.12722

  62. 62.

    Mathew A Kurane I Green S Stephens HA Vaughn DW Kalayanarooj S. Predominance of HLA-restricted cytotoxic T-lymphocyte responses to serotype-cross-reactive epitopes on nonstructural proteins following natural secondary dengue virus infection. J Virol. (1998 ) 72:3999–4004.

    Not in our library10.1128/jvi.72.5.3999-4004.1998

  63. 63.

    Loke H Bethell DB Phuong CX Dung M Schneider J White NJ. Strong HLA class I–restricted T cell responses in dengue hemorrhagic fever: a double-edged sword? J Infect Dis. (2001 ) 184:1369–73.

    Not in our library10.1086/324320

  64. 64.

    Gagnon SJ Zeng W Kurane I Ennis FA. Identification of two epitopes on the dengue 4 virus capsid protein recognized by a serotype-specific and a panel of serotype-cross-reactive human CD4+ cytotoxic T-lymphocyte clones. J Virol. (1996 ) 70:141–7.

    Not in our library10.1128/jvi.70.1.141-147.1996

  65. 65.

    Wen JS Jiang LF Zhou JM Yan HJ Fang DY. Computational prediction and identification of dengue virus-specific CD4. (+) T-cell epitopes. Virus Res. (2008 ) 132:42–8.

    Not in our library10.1016/j.virusres.2007.10.010

  66. 66.

    Bowerman NA Falta MT Mack DG Kappler JW Fontenot AP. Mutagenesis of beryllium-specific TCRs suggests an unusual binding topology for antigen recognition. J Immunol. (2011 ) 187:3694–703.

    Not in our library10.4049/jimmunol.1101872

  67. 67.

    Rivino L Kumaran EA Thein TL Too CT Gan VC Hanson BJ. Virus-specific T lymphocytes home to the skin during natural dengue infection. Sci Transl Med. (2015 ) 7:278ra35.

    Not in our library10.1126/scitranslmed.aaa0526

  68. 68.

    Malavige GN Jeewandara C Alles KM Salimi M Gomes L Kamaladasa A. Suppression of virus specific immune responses by IL-10 in acute dengue infection. PLoS Negl Trop Dis. (2013 ) 7:e2409.

    Not in our library10.1371/journal.pntd.0002409

  69. 69.

    Grifoni A Pham J Sidney J O'Rourke PH Paul S Peters B. Prior Dengue virus exposure shapes T cell immunity to Zika virus in humans. J Virol. (2017 ) 91:e01469–17.

    Not in our library10.1128/jvi.01469-17

  70. 70.

    Turtle L Bali T Buxton G Chib S Chan S Soni M. Human T cell responses to Japanese encephalitis virus in health and disease. J Exp Med. (2016 ) 213:1331–52.

    Not in our library10.1084/jem.20151517

  71. 71.

    Turtle L Tatullo F Bali T Ravi V Soni M Chan S. Cellular immune responses to live attenuated japanese encephalitis. (JE) Vaccine SA14–14-2 in adults in a je/dengue co-endemic area. PLoS Negl Trop Dis. (2017 ) 11:e0005263.

    Not in our library10.1371/journal.pntd.0005263

  72. 72.

    Weiskopf D Yauch LE Angelo MA John DV Greenbaum JA Sidney J. Insights into HLA-restricted T cell responses in a novel mouse model of dengue virus infection point toward new implications for vaccine design. J Immunol. (2011 ) 187:4268–79.

    Not in our library10.4049/jimmunol.1101970

  73. 73.

    Weiskopf D Cerpas C Angelo MA Bangs DJ Sidney J Paul S. Human CD8+ T-cell responses against the 4 dengue virus serotypes are associated with distinct patterns of protein targets. J Infect Dis. (2015 ) 212:1743–51.

    Not in our library10.1093/infdis/jiv289

  74. 74.

    Rivino L Tan AT Chia A Kumaran EA Grotenbreg GM MacAry PA. Defining CD8+ T cell determinants during human viral infection in populations of Asian ethnicity. J Immunol. (2013 ) 191:4010–9.

    Not in our library10.4049/jimmunol.1301507

  75. 75.

    Appanna R Huat TL See LL Tan PL Vadivelu J Devi S. Cross-reactive T-cell responses to the nonstructural regions of dengue viruses among dengue fever and dengue hemorrhagic fever patients in Malaysia. Clin Vaccine Immunol. (2007 ) 14:969–77.

    Not in our library10.1128/cvi.00069-07

  76. 76.

    Weiskopf D Angelo MA Bangs DJ Sidney J Paul S Peters B. The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes. J Virol. (2015 ) 89:120–8.

    Not in our library10.1128/jvi.02129-14

  77. 77.

    Weiskopf D Angelo MA Grifoni A O'Rourke PH Sidney J Paul S. HLA-DRB1 alleles are associated with different magnitudes of dengue virus-specific CD4+ T-cell responses. J Infect Dis. (2016 ) 214:1117–24.

    Not in our library10.1093/infdis/jiw309

  78. 78.

    Angelo MA Grifoni A O'Rourke PH Sidney J Paul S Peters B. Human CD4+ T cell responses to an attenuated tetravalent dengue vaccine parallel those induced by natural infection in magnitude, HLA restriction, and antigen specificity. J Virol. (2017 ) 91:e02147–16.

    Not in our library10.1128/jvi.02147-16

  79. 79.

    Grifoni A Moore E Voic H Sidney J Phillips E Jadi R. Characterization of magnitude and antigen specificity of HLA-DP, DQ, and DRB3/4/5 Restricted DENV-Specific CD4+ T Cell Responses. Front Immunol. (2019 ).

    Not in our library10.3389/fimmu.2019.01568

  80. 80.

    Malavige GN McGowan S Atukorale V Salimi M Peelawatta M Fernando N. Identification of serotype-specific T cell responses to highly conserved regions of the dengue viruses. Clin Exp Immunol. (2012 ) 168:215–23.

    Not in our library10.1111/j.1365-2249.2012.04566.x

  81. 81.

    Grifoni A Angelo M Sidney J Paul S Peters B de Silva AD. Patterns of cellular immunity associated with experimental infection with rDEN2Delta30. (Tonga/74) support its suitability as a human dengue virus challenge strain. J Virol. (2017 ) 91:e02133–16.

    Not in our library10.1128/jvi.02133-16

  82. 82.

    Osorio JE Wallace D Stinchcomb DT. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone. Exp Rev Vaccines. (2016 ) 15:497–508.

    Not in our library10.1586/14760584.2016.1128328

  83. 83.

    Kirkpatrick BD Durbin AP Pierce KK Carmolli MP Tibery CM Grier PL. Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults. J Infect Dis. (2015 ) 212:702–10.

    Not in our library10.1093/infdis/jiv082

  84. 84.

    Dhanda SK Vita R Ha B Grifoni A Peters B Sette A ImmunomeBrowser: a tool to aggregate and visualize complex and heterogeneous epitopes in reference protein. Bioinformatics. (2018 ) 34:3931–3.

    Not in our library10.1093/bioinformatics/bty463

  85. 85.

    Weiskopf D Angelo MA Sidney J Peters B Shresta S Sette A. Immunodominance changes as a function of the infecting dengue virus serotype and primary versus secondary infection. J Virol. (2014 ) 88:11383–94.

    Not in our library10.1128/jvi.01108-14

  86. 86.

    Carrasco Pro S Sidney J Paul S Lindestam Arlehamn C Weiskopf D Peters B. Automatic generation of validated specific epitope sets. J Immunol Res. (2015 ) 2015:763461.

    Not in our library10.1155/2015/763461

  87. 87.

    Hatch S Endy TP Thomas S Mathew A Potts J Pazoles P. Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection. J Infect Dis. (2011 ) 203:1282–91.

    Not in our library10.1093/infdis/jir012

  88. 88.

    Schenkel JM Masopust D. Tissue-resident memory T cells. Immunity. (2014 ) 41:886–97.

    Not in our library10.1016/j.immuni.2014.12.007

  89. 89.

    Chandele A Sewatanon J Gunisetty S Singla M Onlamoon N Akondy RS. Characterization of human CD8 T cell responses in dengue virus-infected patients from India. J Virol. (2016 ) 90:11259–78.

    Not in our library10.1128/jvi.01424-16

  90. 90.

    Tian Y Babor M Lane J Seumois G Liang S Goonawardhana NDS. Dengue-specific CD8+ T cell subsets display specialized transcriptomic and TCR profiles. J Clin Invest. (2019 ) 130:1727–41.

    Not in our library10.1172/jci123726

  91. 91.

    Kaech SM Cui W. Transcriptional control of effector and memory CD8+ T cell differentiation. Nat Rev Immunol. (2012 ) 12:749–61.

    Not in our library10.1038/nri3307

  92. 92.

    Swain SL McKinstry KK Strutt TM. Expanding roles for CD4. (+) T cells in immunity to viruses. Nat Rev Immunol. (2012 ) 12:136–48.

    Not in our library10.1038/nri3152

  93. 93.

    Tian Y Zajac AJ. IL-21 and T cell differentiation: consider the context. Trends Immunol. (2016 ) 37:557–68.

    Not in our library10.1016/j.it.2016.06.001

  94. 94.

    Lindow JC Borochoff-Porte N Durbin AP Whitehead SS Fimlaid KA Bunn JY. Primary vaccination with low dose live dengue 1 virus generates a proinflammatory, multifunctional T cell response in humans. PLoS Negl Trop Dis. (2012 ) 6:e1742.

    Not in our library10.1371/journal.pntd.0001742

  95. 95.

    Gwinn W Sun W Innis BL Caudill J King AD. Serotype-specific T. (H)1 responses in recipients of two doses of candidate live-attenuated dengue virus vaccines. Am J Trop Med Hyg. (2003 ) 69:39–47.

    Not in our library10.4269/ajtmh.2003.69.39

  96. 96.

    Duangchinda T Dejnirattisai W Vasanawathana S Limpitikul W Tangthawornchaikul N Malasit P. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc Natl Acad Sci USA. (2010 ) 107:16922–7.

    Not in our library10.1073/pnas.1010867107

  97. 97.
    A 20-Gene Set Predictive of Progression to Severe Dengue · 2019
    Not checked
  98. 98.

    Patil VS Madrigal A Schmiedel BJ Clarke J O'Rourke P de Silva AD. Precursors of human CD4. (+) cytotoxic T lymphocytes identified by single-cell transcriptome analysis. Sci Immunol. (2018 ) 3:eaan8664.

    Not in our library10.1126/sciimmunol.aan8664

  99. 99.
    Unique phenotypes and clonal expansions of human CD4 effector memory T cells re-expressing CD45RA · 2017
    No notice
  100. 100.

    Plitas G Rudensky AY. Regulatory T cells: differentiation and function. Cancer Immunol Res. (2016 ) 4:721–5.

    Not in our library10.1158/2326-6066.cir-16-0193

  101. 101.

    Zeng H Zhang R Jin B Chen L. Type 1 regulatory T cells: a new mechanism of peripheral immune tolerance. Cell Mol Immunol. (2015 ) 12:566–71.

    Not in our library10.1038/cmi.2015.44

  102. 102.

    Luhn K Simmons CP Moran E Dung NT Chau TN Quyen NT. Increased frequencies of CD4+ CD25. (high) regulatory T cells in acute dengue infection. J Exp Med. (2007 ) 204:979–85.

    Not in our library10.1084/jem.20061381

  103. 103.

    Jayaratne HE Wijeratne D Fernando S Kamaladasa A Gomes L Wijewickrama A. Regulatory T-cells in acute dengue viral infection. Immunology. (2018 ) 154:89–97.

    Not in our library10.1111/imm.12863

  104. 104.

    Crotty S. T follicular helper cell differentiation, function, and roles in disease. Immunity. (2014 ) 41:529–42.

    Not in our library10.1016/j.immuni.2014.10.004

  105. 105.

    Locci M Havenar-Daughton C Landais E Wu J Kroenke MA Arlehamn CL. Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity. (2013 ) 39:758–69.

    Not in our library10.1016/j.immuni.2013.08.031

  106. 106.

    Obeng-Adjei N Portugal S Tran TM Yazew TB Skinner J Li S. Circulating Th1-Cell-type Tfh cells that exhibit impaired B cell help are preferentially activated during acute malaria in children. Cell Rep. (2015 ) 13:425–39.

    Not in our library10.1016/j.celrep.2015.09.004

  107. 107.

    Roychoudhuri R Clever D Li P Wakabayashi Y Quinn KM Klebanoff CA. BACH2 regulates CD8. (+) T cell differentiation by controlling access of AP-1 factors to enhancers. Nat Immunol. (2016 ) 17:851–60.

    Not in our library10.1038/ni.3441

  108. 108.

    Havenar-Daughton C Carnathan DG Torrents de la Pena A Pauthner M Briney B Reiss SM. Direct probing of germinal center responses reveals immunological features and bottlenecks for neutralizing antibody responses to HIV Env trimer. Cell Rep. (2016 ) 17:2195–209.

    Not in our library10.1016/j.celrep.2016.10.085

  109. 109.

    Bentebibel SE Lopez S Obermoser G Schmitt N Mueller C Harrod C. Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination. Sci Transl Med. (2013 ) 5:176ra32.

    Not in our library10.1126/scitranslmed.3005191

  110. 110.

    Onabajo OO George J Lewis MG Mattapallil JJ. Rhesus macaque lymph node PD-1. (hi)CD4+ T cells express high levels of CXCR5 and IL-21 and display a CCR7. (lo)ICOS+Bcl6+ T-follicular helper. (Tfh) cell phenotype. PLoS ONE. (2013 ) 8:e59758.

    Not in our library10.1371/journal.pone.0059758

  111. 111.

    Crotty S. A brief history of T cell help to B cells. Nat Rev Immunol. (2015 ) 15:185–9.

    Not in our library10.1038/nri3803

  112. 112.

    Schmitt N Ueno H. Blood Tfh cells come with colors. Immunity. (2013 ) 39:629–30.

    Not in our library10.1016/j.immuni.2013.09.011

  113. 113.

    Dan JM Lindestam Arlehamn CS Weiskopf D da Silva Antunes R Havenar-Daughton C Reiss SM A cytokine-independent approach to identify antigen-specific human germinal center t follicular helper cells and rare antigen-specific CD4+ T cells in blood. J Immunol. (2016 ) 197:983–93.

    Not in our library10.4049/jimmunol.1600318

  114. 114.

    Havenar-Daughton C Reiss SM Carnathan DG Wu JE Kendric K Torrents de la Pena A. Cytokine-independent detection of antigen-specific germinal center T follicular helper cells in immunized nonhuman primates using a live cell activation-induced marker technique. J Immunol. (2016 ) 197:994–1002.

    Not in our library10.4049/jimmunol.1600320

  115. 115.

    Haltaufderhyde K Srikiatkhachorn A Green S Macareo L Park S Kalayanarooj S. Activation of peripheral T follicular helper cells during acute dengue virus infection. J Infect Dis. (2018 ) 218:1675–85.

    Not in our library10.1093/infdis/jiy360

  116. 116.

    Saron WAA Rathore APS Ting L Ooi EE Low J Abraham SN. Flavivirus serocomplex cross-reactive immunity is protective by activating heterologous memory CD4 T cells. Sci Adv. (2018 ) 4:eaar4297.

    Not in our library10.1126/sciadv.aar4297

Cited by papers we hold 5

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.